Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 10, No 3 (2017) Decision modelling for the evaluation of diabetes outcomes Abstract  similar documents
A. A. Mosikian, W. Zhao, T. L. Galankin, A. S. Kolbin
"... The process of decision modelling in diabetes mellitus (DM) is often complicated by comorbidity ..."
 
Vol 9, No 1 (2016) MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016 Abstract  similar documents
A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum
"... tools for modelling reimbursement system decisions. At the mean time the existing system of decision ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT Abstract  similar documents
N. K. Mazina, P. V. Mazin, Yu. V. Kislitsin, E. M. Markova
"... the chances of successful result (HR=3.1 [2.0; 4.9], p=0.000). Pharmacoeconomic modelling (a decision tree ..."
 
Vol 7, No 4 (2014) MODELING IN CLINICO-ECONOMIC ANALYSIS OF MEDICAL ORGANIZATIONAL TECHNOLOGIES Abstract  similar documents
M. A. Shapovalova, A. R. Umerova, V. A. Bondarev, L. R. Koretskaya
"... decision tree and Markov model we used for calculating the anticipated costs when comparing two ..."
 
Vol 6, No 2 (2013) FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS Abstract  similar documents
A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure
"... Цель работы – создать модель исходов сахарного диабета 2-го типа, валидированную для применения в ..."
 
Vol 9, No 3 (2016) HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE Abstract  similar documents
A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina
"... conditions. Markov modelling and CEA accounting for direct medical costs were used. The effectiveness ..."
 
Vol 11, No 1 (2018) Modeling microbial drug-resistance: from mathematics to pharmacoeconomics Abstract  similar documents
Yu. M. Gomon, M. A. Arepyeva, Yu. E. Balykina, A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, S. V. Sidorenko
"... антибактериальной терапии. С помощью математического моделирования спрогнозирована  динамика резистентности E. coli ..."
 
Vol 9, No 1 (2016) COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN Abstract  similar documents
V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva
"... , improves the quality of life of patients, adding 0.73 QALY per patient. Modelling suggests ..."
 
Vol 11, No 4 (2018) Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach Abstract  similar documents
A. G. Tolkushin, S. K. Zyryanov, N. L. Pogudina, M. V. Davydovskaya
"... . При рассмотрении отдельных КЭИ обращали внимание на вид модели, детали методики моделирования ..."
 
Vol 9, No 3 (2016) EARLY HEALTH TECHNOLOGIES ASSESSMENT — NEW APPROACH TO IMPROVING THE EFFICIENCY OF THE MEDICAL TECHNOLOGY DEVELOPMENT PROCESS Abstract  similar documents
N. Z. Musina, V. V. Omelyanovskiy, A. V. Krasheninnikova
"... симуляция клинических исследований (СКИ) осуществляется с помощью математических моделей, которые ..."
 
Vol 7, No 4 (2014) APPLICATION OF MULTIPLE-CRITERIA ANALYSIS FOR OPTIMIZATION OF FINANCING OF RARE DISEASES Abstract  similar documents
V. V. Omelyanovskiy, V. K. Fedyaeva, O. Yu. Rebrova
"...  objectivity and transparency of decisions in the area of rare diseases. The main advantage of multiple ..."
 
Vol 6, No 2 (2013) PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION Abstract  similar documents
V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina
"... использованием препаратов антиретровирусной терапии (АРТ). Разработана детерминистиче ская модель распространения ..."
 
Vol 5, No 1 (2012) PHARMACOECONOMICS AS A NEW INSTRUMENT OF PHARMACEUTICAL MARKETING Abstract  similar documents
M. V. Protsenko, N. I. Koroleva
"... to convey to health care decision makers and how to bring this information full, correct, and easy ..."
 
Vol 6, No 2 (2013) HTA CORE MODEL Abstract  similar documents
R. I. Yagudina, T. Yu. Nor, A. D. Sevostyanov
"... Базовая Модель ОТЗ – система стандартизированной оценки технологий здравоохранения (ОТЗ ..."
 
Vol 10, No 3 (2017) Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients Abstract  similar documents
N. K. Mazina, P. V. Mazin
"... . The pharmacoeconomic advantages of enzalutamide over the two other agents are supported by the «decision tree» model ..."
 
Vol 7, No 2 (2014) PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Abstract  similar documents
A. S. Kolbin, I. A. Vilum, Yu. E. Balykina, M. A. Proskurin
"... проведено с позиции государственной системы здравоохранения с помощью математического моделирования ..."
 
Vol 7, No 3 (2014) MODELI NG CLINICAL AND ECONOMIC OUTCOMES OF TESTING FOR LTBI WITH T-SPOT.TB IN IMMUNOCOMPROMISED CHILDREN Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva, V. V. Omelyanovsky, G. R. Khachatryan
"... иммуноскомпрометированных детей. Материалы и методы: построена модель, позволяющая прогнозировать результаты тестирования ..."
 
Vol 11, No 4 (2018) Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease Abstract  similar documents
V. I. Ignatyeva, S. V. Moiseev, N. M. Bulanov, E. A. Karovajkina, A S. Moiseev
"... наличия ФЗТ и времени ее начала. Материалы и методы. В модели, построенной на основании опубликованных ..."
 
Vol 5, No 2 (2012) COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS Abstract  similar documents
A. V. Rudakova
"... к витамину D, анализ эффективно- сти затрат, марковская модель. Цель исследования: оценка ..."
 
Vol 5, No 2 (2012) WORKING OUT OF STRATEGY OF STOREKEEPING OF PHARMACEUTICAL FIRM Abstract  similar documents
A. I. Borodin
"... использованием динамических моделей, периодических и с критическим уровнем. Эффективность получена за счет ..."
 
Vol 5, No 1 (2012) EСOLOGO-ECONOMIC PROBLEMS OF TECHNOGENIC INFLUENCE OF POLLUTION ON DISEASE OF THE POPULATION Abstract  similar documents
A. I. Borodin, E. M. Ovchinnikov
"... decision-making on maintenance of quality of environment ..."
 
Vol 10, No 4 (2017) PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... математическая модель, описывающая текущий подход к терапии гемофилии А (пациенты в РФ в 2017 г. с учетом их ..."
 
Vol 11, No 3 (2018) Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies Abstract  similar documents
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov
 
Vol 11, No 3 (2018) What is the role of antineoplastic drug safety in reimbursement decision making? Abstract  similar documents
A. S. Kolbin, A. A. Kurylev
"... (Aes). The question whether drug safety is taken into consideration by decision makers is still open ..."
 
Vol 7, No 2 (2014) PARAMETERS OF HEALTH CARE SYSTEMS Abstract  similar documents
V. V. Omelyanovskiy, I. V. Maksimova, A. P. Tatarinov
"... в любой стране выбор оптимальной модели здравоохранения имеет принципиальное значение для ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical analysis of use of the low-molecular weight heparins for prevention of the venous tromboembolism in the conditions of multidisciplinary hospital Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... были построены две фармакоэкономические модели. Основная модель – оценка эффективности стратегий ..."
 
Vol 11, No 3 (2018) The concept of multi-criteria analysis of decision-making in the current system of health technology assessment in Russia Abstract  similar documents
V. V. Omelyanovsky, V. K. Fedyaeva, N. Z. Musina
"... forward. We conclude that the HTA methodology in Russia is consistent with the multi-criteria decision ..."
 
Vol 12, No 3 (2019) Diagnosis-related groups and payments for the treatment of malignant neoplasms in the model of 2019 Abstract  similar documents
D. V. Fedyaev , V. V. Omelyanovskiy , M. L. Lazareva , Yu. V. Seryapina, Yu. A. Ledovskikh
"... В статье рассматривается развитие модели клинико-статистических групп (КСГ) и заложенных в нее ..."
 
Vol 10, No 1 (2017) EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... проводились на основании MS Excel-модели. Моделирование производилось на 3-летний период. В анализе «затраты ..."
 
Vol 12, No 2 (2019) Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers Abstract  similar documents
E. V. Radchenko, A. S. Kolbin
 
Vol 8, No 1 (2015) PAYMENT OF NEW EXPENSIVE TECHNOLOGIES IN HEALTH CARE ON THE BASIS OF RISKS -SHARING AGREEMENTS: POSSIBILITIES OF APPLICATION IN THE RUSSIAN FEDERATION Abstract  similar documents
L. S. Melnikova
"... of decision system, which element is necessary for introduction of risk sharing agreements. The article also ..."
 
Vol 9, No 1 (2016) PROSPECTS FOR THE USE OF METHODS OF ECONOMIC EVALUATION AT THE STAGE OF PLANNING AND ORGANISATION OF CLINICAL TRIALS Abstract  similar documents
N. Z. Musina, V. V. Tarasov
"... применением математического моделирования. Реализация дан- ного подхода позволяет учитывать результаты ..."
 
Vol 10, No 3 (2017) The strategies of drug supply for patients with chronic hepatitis C Abstract  similar documents
E. V. Kornilova, A. D. Ermolaeva, M. G. Rusanova, D. A. Andreev, M. V. Davydovskaya, T. N. Ermolaeva, A. g Pokatilo, K. I. Polyakova, V. A. Dubovtseva, K. А. Kokushkin, A. V. Devyatkin
 
Vol 11, No 2 (2018) Regional adaptation of the federal model of reimbursement for medical assistance based on clinical statistical groups: hospitalization of patients in need of genetically enginered biological preparations Abstract  similar documents
M. V. Sura, T. N. Ignatova, N. S. Rudneva, Yu. N. Sukhanova, N. G. Ulyanova, A. S. Khudyaev, V. A. Shelyakin, D. V. Scherbakov
"... Модель финансирования медицинской помощи по клинико-статистическим группам (КСГ) в 2018 г ..."
 
Vol 12, No 1 (2019) Individual cost accounting in the management of medical organizations Abstract  similar documents
I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali
"... a close internal management of financial activity. This function helps decision-makers: control the use ..."
 
Vol 8, No 4 (2015) PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER Abstract  similar documents
D. A. Zhukov
"... .9 billion rubles (42.2 million EUR). According to the generated modelling, the pneumococcal (PPSV23 ..."
 
Vol 10, No 3 (2017) Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis Abstract  similar documents
E. V. Biryukova, V. I. Ignat’eva
"... created a “decision tree” model that allowed us to calculate the costs of 48-week insulin therapy in 1000 ..."
 
Vol 8, No 4 (2015) APPROACHES TO THE CONCEPTS OF PRODUCTIVITY, EFFICIENCY AND EFFECTIVENESS IN THE FIELD OF SCIENTIFIC RESEARCH AND DEVELOPMENT Abstract  similar documents
O. F. Seliverstova
"... decision-making needs to be redressed. Recommendations on fixing these concepts in normative legal ..."
 
Vol 8, No 2 (2015) REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS Abstract  similar documents
Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev
"... definition of a rare disease and no universal approach to orphan drugs legislation. As a result, decision ..."
 
Vol 9, No 3 (2016) COPAYMENTS OF THE CITIZENS IN HEALTHCARE SYSTEM: INTERNATIONAL PRACTICE Abstract  similar documents
A. P. Tatarinov, D. V. Lukyantseva, L. S. Melnikova, V. V. Omelyanovskii
"... , соплатежи, сооплата, сострахование, франшизы, международный опыт, модель здравоохранения, система ..."
 
Vol 11, No 1 (2018) CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation Abstract  similar documents
A. A. Kurylev, B. V. Andreev, A. S. Kolbin, O. V. Limankin
"... decision-making model was created. The model calculates direct medical costs for the patient care ..."
 
Vol 9, No 3 (2016) CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov
"... Цели исследования: 1) разработать модель для прогнозирования влияния применения лакосамида в ..."
 
Vol 9, No 2 (2016) MANAGEMENT ASPECT OF THE PROBLEM OF NARCOTIC DRUGS USE Abstract  similar documents
S. Yu. Soboleva, A. V. Sobolev, I. A. Kaminskaya
"... imbalance in the system of record and control of narcotic drugs and suggests using in its decision real ..."
 
Vol 12, No 1 (2019) Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan Abstract  similar documents
T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova
"... . Материалы и методы. В модели проведен анализ влияния на бюджет, где исходным состоянием является текущая ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... обеспечения Microsoft Excel разработаны две модели для проведения анализа минимизации затрат (модель 1) и ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... анализ влияния на бюджет. Расчеты проводились в модели, построенной в Microsoft Excel. В анализе «затраты ..."
 
Vol 8, No 1 (2015) BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... стратегией, с точки зрения анализа «влияние на бюджет»: при горизонте моделирования 25 мес. применение ..."
 
Vol 6, No 4 (2013) Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа Abstract  similar documents
A. Yu. Kulikov, I. V. Novikov
"... , моделирование. Метод фармакоэкономического анализа – «затраты-полезность». Горизонт моделирования – 10 лет ..."
 
Vol 7, No 3 (2014) ECONOMIC JUSTIFICATION FOR TELEHEALTH TECHNOLOGY USE FOR PREVENTIVE MEDICAL EXAMINATION OF THE POPULATION IN REMOTE REGIONS Abstract  similar documents
D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky
"... модель предполагает сравнение двух возможных стратегий проведения диспансеризации пациентов с применением ..."
 
1 - 50 of 131 Items 1 2 3 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)